Shield Therapeutics (STX) Competitors

Shield Therapeutics (LON:STX) and El Oro (LON:ELX) are both small-cap computer hardware companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, dividends, earnings, valuation, profitability, risk and institutional ownership.

Is STX or ELX more profitable?

El Oro has a net margin of 0.00% compared to Shield Therapeutics' net margin of -173.43%. El Oro's return on equity of 0.00% beat Shield Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Shield Therapeutics	-173.43%	-470.50%	-47.85%
El Oro	N/A	N/A	N/A

Which has better earnings & valuation, STX or ELX?

El Oro has lower revenue, but higher earnings than Shield Therapeutics. Shield Therapeutics is trading at a lower price-to-earnings ratio than El Oro, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Shield Therapeutics	£41.50M	2.10	-£36.28M	-£0.02	-410.00
El Oro	-£7.25M	0.00	N/A	-£2.50	N/A

Does the media favor STX or ELX?

In the previous week, Shield Therapeutics had 5 more articles in the media than El Oro. MarketBeat recorded 5 mentions for Shield Therapeutics and 0 mentions for El Oro. Shield Therapeutics' average media sentiment score of 0.40 beat El Oro's score of 0.00 indicating that Shield Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Shield Therapeutics	Neutral
El Oro	Neutral

Do analysts rate STX or ELX?

Shield Therapeutics presently has a consensus price target of GBX 15, suggesting a potential upside of 82.93%. Given Shield Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Shield Therapeutics is more favorable than El Oro.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Shield Therapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
El Oro	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Do institutionals and insiders hold more shares of STX or ELX?

6.7% of Shield Therapeutics shares are owned by institutional investors. 3.0% of Shield Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Shield Therapeutics beats El Oro on 9 of the 13 factors compared between the two stocks.